NorthlineHealth
Join
← FormularyTracking · Category 2

Melanocortin Receptor Agonist · Sexual Health

PT-141

Libido / sexual health

Status
On watchlist — not yet prescribable
Get notified on reclassification

Mechanism

PT-141 (bremelanotide) is a cyclic heptapeptide analogue of α-MSH acting on melanocortin receptors MC1R, MC3R, and MC4R. Unlike PDE5 inhibitors, it acts centrally in the hypothalamus to stimulate sexual arousal, independent of vascular mechanisms. FDA-approved as Vyleesi for hypoactive sexual desire disorder in premenopausal women.

Indications

→Hypoactive sexual desire disorder (HSDD)
→Erectile dysfunction (off-label)
→Libido enhancement in men and women
→Sexual arousal via central mechanism

Regulatory status

Bremelanotide (PT-141) is FDA-approved as Vyleesi for HSDD. Despite this, compounded versions are on the 503A Category 2 list, making compounded preparations non-compliant. The brand product requires a prescription.

References

01Diamond LE, et al. Effects of drug and sexual stimulation on genital and subjective sexual response in nondysfunctional men. Urology. 2004.
02FDA 503A Category 2 — compounded form ineligible.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.